Pluvicto (177Lu-PSMA-617)
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for Pluvicto (177Lu-PSMA-617), covering 2025-09-09 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1]